Fu EL, Mastrorilli J, Bykov K, Wexler DJ, et al. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes. Kidney Int 2023 Dec 13:S0085-2538(23)00865-7. doi: 10.1016/j.kint.2023.
PMID: 38101515